2026 MaTOS GU | Session VI | Challenging Case-Based Panel Discussion
Overview
Case 1: Dr. Jang presented 72M with recurrent high-risk prostate cancer: PSMA+ nodes, rapid PSA rise; biopsy confirmed disease, enrolled in trial after ADT vs MDT debate.
Case 2: Dr. Srinivas presented 67M with high-risk prostate cancer: PSMA+ node, Gleason 4+3; chose radiation + 18 mo ADT; panel debated surgery, PET role, and genomics.
Case 3: Dr. Maughan presented an advanced prostate cancer case: BRCA2 VUS, TP53 mutation; treated with chemo+PARP, achieved CR but developed MDS; panel stressed biopsy and cautious sequencing.
Case 4: Dr. Vaishampayan presented a metastatic prostate cancer case: liver mets, PTEN loss; initial ADT/ARPI response, later progression; Pluvicto led to CR and undetectable PSA.
Case 2: Dr. Srinivas presented 67M with high-risk prostate cancer: PSMA+ node, Gleason 4+3; chose radiation + 18 mo ADT; panel debated surgery, PET role, and genomics.
Case 3: Dr. Maughan presented an advanced prostate cancer case: BRCA2 VUS, TP53 mutation; treated with chemo+PARP, achieved CR but developed MDS; panel stressed biopsy and cautious sequencing.
Case 4: Dr. Vaishampayan presented a metastatic prostate cancer case: liver mets, PTEN loss; initial ADT/ARPI response, later progression; Pluvicto led to CR and undetectable PSA.
Target Audience
Physicians
This material is non‑CME, no credits are available, and a certificate will not be provided upon completion.
Faculty
Speakers and Panelists:
Albert Jang, MD
Benjamin Maughan, MD, PharmD
Sandy Srinivas, MD
Ulka Vaishampayan, MD
Date of Release
March 20th, 2026
%2016.47.03-1770752981975.webp&w=3840&q=75)
